Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acromegaly
Data on acromegaly published by J.A. Verhelst and colleagues
March 23rd, 2008
"Dopamine agonists are effective in some patients with acromegaly and in this condition treatment is considered to be chronic. We describe two acromegalic patients who responded adequately to the long-acting dopamine agonist cabergoline, but surprisingly maintained normal GH and IGF-I levels once therapy was discontinued after 42 and 76 months because of possibly related side effects," scientists in Antwerp, Belgium report. "A 32-year-old woman with mild acromegaly (IGF-I: 423 mu g/l, GH after OGTT: 2.5 mu g/l, adenoma 4 mm) was treated with cabergoline as primary therapy and reached safe GH levels (2 mu g/l or less) and normal IGF-I levels with 3.5 mg cabergoline...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-23)
|
